Soft Tissue Sarcomas
Oncology
Prevalence
30.0 / 100K
2 drugs in development·2 companies·0 clinical trials
Drug Pipeline by Phase
Phase 2(1)
| Drug | Company |
|---|---|
| sotigalimab | Apexigen, Inc. (APGN) |
Phase 1(1)
| Drug | Company |
|---|---|
| Peposertib | Merus N.V. (MRUS) |
Compare drugs
Frequently asked questions
How many drugs are in development for Soft Tissue Sarcomas?
BioSniper tracks 2 drugs in development for Soft Tissue Sarcomas across 2 companies.
What is the prevalence of Soft Tissue Sarcomas?
The estimated prevalence of Soft Tissue Sarcomas is approximately 30.0 per 100,000 population.
Deep-dive into Soft Tissue Sarcomas
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis